Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27994268 | 0.89 | F2 (0.43) | KMT2AMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL10086158 | 0.89 | ALDH1A1 (0.41) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL19157539 | 0.82 | ALDH1A1 (0.39) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL17039628 | 0.81 | NQO2 (0.49) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL19157146 | 0.78 | SMN1; SMN2 (0.43) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL6774848 | 0.75 | MEN1 (0.42) | KMT2AMEN1NPC1F2BRD4 | |
| SCHEMBL15107067 | 0.75 | ALDH1A1 (0.47) | KMT2AMEN1NPC1ALDH1A1MAPT | |
| SCHEMBL506325 | 0.74 | PRKCI (0.46) | KMT2AMEN1ALDH1A1MAPTGAA | |
| SCHEMBL506730 | 0.73 | F2 (0.68) | F2 | |
| SCHEMBL18380902 | 0.72 | SMN1; SMN2 (0.42) | KMT2AMEN1ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3195876-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-3195876-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-2525812-B1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2017-01-18 | — | — | EP | disclosed |
| EP-2525812-B1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-20150210778-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150210778-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INT (DE) | 2015-07-30 | — | — | US | disclosed |
| US-9034822-B2 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds | BOEHRINGER IGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034822-B2 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds | BOEHRINGER IGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-20140377265-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-20140377265-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-20130289248-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289248-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-8486398-B2 | Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8486398-B2 | Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20120276123-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| WO-2012130834-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012130834-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-04 | — | — | WO | disclosed |
| US-20120027780-A1 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011089183-A2 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011089183-A2 | ANTICOAGULANT ANTIDOTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210778-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | KMT2A 2718/4885MEN1 2791/4885NPC1 3655/4885 |
| US-20120027780-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | KMT2A 2718/4885MEN1 2791/4885NPC1 3655/4885 |
| US-20140377265-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | KMT2A 2718/4885MEN1 2791/4885NPC1 3655/4885 |
| US-20130289248-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | KMT2A 2718/4885MEN1 2791/4885NPC1 3655/4885 |
| US-20120276123-A1 | ANTICOAGULANT ANTIDOTES | SERPINC1, KCNH1, ANTXR2 | KMT2A 2718/4885MEN1 2791/4885NPC1 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.